Financial terms of the deal weren’t disclosed. Perrigo said Wednesday that it expects to finalize the Geiss, Destin & Dunn (GDD) transaction by the end of August.
Based in Peachtree, Ga., GDD serves wholesalers, non-chain retailers and the institutional market, with coverage in all 50 states. The company’s main product line includes more than 1,500 OTC and personal care items under the GoodSense brand.
GDD also offers a roster of diabetic care products under such brands as Monoject, Kendall, Dex4, Clickfine, Monolet and Kendall T.E.D., as well as pet health care items under the brands Swisspers, Germ-X, Arm & Hammer, Plackers and Swan.
“Today’s acquisition of GDD, while relatively small in transaction value compared to other acquisitions we’ve made, further strengthens and diversifies our U.S. distribution and retail network, providing us direct access to the non-mass retail market,” stated Perrigo chief executive officer John Hendrickson. “While we currently distribute product to this channel through GDD, I am pleased we will now bring the management of this business completely in-house.”